Eli Lilly's Retatrutide Shows Promising Results in Obesity Drug Trials
Eli Lilly’s Next-Gen Obesity Drug Shows Promising Trial Results in Race Beyond Ozempic
Image: Times Now News
Eli Lilly and Company's experimental obesity drug, retatrutide, has shown promising results in late-stage clinical trials, with patients losing an average of 28.3% of their body weight over 80 weeks. This next-generation treatment targets three gut hormones, potentially outperforming existing GLP-1 medications like Ozempic. The results could signify a major advancement in obesity treatment.
- 01In a Phase 3 trial with about 2,500 participants, those on the highest dose of retatrutide lost an average of 70 pounds.
- 02Approximately 45% of participants achieved at least 30% weight loss, a result typically associated with bariatric surgery.
- 03Retatrutide targets three hormones: GLP-1, GIP, and glucagon, enhancing its efficacy compared to current treatments.
- 04Patients on a lower dose of retatrutide lost around 19% of their body weight with fewer side effects.
- 05The global market for obesity drugs is projected to exceed $100 billion by the 2030s.
Advertisement
In-Article Ad
Eli Lilly and Company's experimental obesity drug, retatrutide, has produced impressive results in late-stage clinical trials, indicating it may surpass existing GLP-1 medications like Ozempic and Wegovy. In a Phase 3 trial involving approximately 2,500 patients, those taking the highest dose of retatrutide lost an average of 28.3% of their body weight, translating to around 70 pounds over 80 weeks. Notably, nearly 45% of participants achieved a weight loss of at least 30%, a benchmark usually linked to bariatric surgery. Retatrutide's unique mechanism targets three gut hormones—GLP-1, GIP, and glucagon—potentially explaining its efficacy in appetite suppression and calorie burning. Additionally, a lower dose of retatrutide yielded a 19% weight loss with fewer gastrointestinal side effects, which are common in GLP-1 therapies. As the global obesity drug market continues to grow, analysts anticipate that retatrutide could become a significant player in obesity treatment, emphasizing the shift in perception of obesity as a chronic metabolic disease.
Advertisement
In-Article Ad
If approved, retatrutide could provide a new treatment option for individuals struggling with obesity, potentially improving health outcomes and reducing obesity-related complications.
Advertisement
In-Article Ad
Reader Poll
Do you think new obesity drugs should be prioritized in healthcare?
Connecting to poll...
More about Eli Lilly and Company
Eli Lilly reporta resultados prometedores de retatrutide en fase 3 para la obesidad
Investing • May 21, 2026
Eli Lilly Launches Alzheimer's Therapy Donanemab in India for ₹91,688 per Vial
The Economic Times • May 14, 2026
L'action Eli Lilly en hausse grâce à des résultats d'essais cliniques prometteurs
Investing French • May 14, 2026
Read the original article
Visit the source for the complete story.